The Computational Biomedicine group’s vision is to enable benefits for patients through integrated computational and biological modeling. The main objective is to enable translationally-oriented research through strong collaborations at the LIH and abroad. This requires making sense of the large and complex datasets obtained from patients, animal and cell line models. The group’s top priority is the development of novel computational models for cancer patient stratification and drug response prediction using multi-omics data. The scientists within the group lead and enable cross-disciplinary research partnerships, which benefit from their diverse expertise in biological network modeling and analysis; Integrative, large-scale analysis of multi-omics data; and Biostatistics and machine learning.